ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "genomics"

  • Abstract Number: 0766 • ACR Convergence 2024

    Neutrophil Transcriptomics in VEXAS Syndrome

    Chloe Palmer1, Gustaf Wigerblad1, Tom Hill2, Bhavisha Patel3, Emma Groarke4, Neal Young4, Stefania Dell'Orso5 and Peter Grayson6, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, 3National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, 4National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, 5National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 6National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD

    Background/Purpose: Vacuoles, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations of the ubiquitin-like modifier activating enzyme 1 (UBA1) gene and…
  • Abstract Number: 0960 • ACR Convergence 2024

    The Esophageal Epithelium in Systemic Sclerosis: Cellular and Molecular Dysregulation Revealed by Single-Cell RNA Sequencing

    Matthew Dapas1, Margarette Clevenger1, Hadijat Makinde2, Tyler Therron1, Dustin Carlson1, Mary Carns3, Kathleen Aren3, Carrie Richardson2, Cenfu Wei2, Lutfiyya Muhammad4, John Pandolfino1, Harris Perlman2, Deborah Winter5 and Marie-Pier Tetreault1, 1Northwestern University, Chicago, 2Northwestern University, Chicago, IL, 3Northwestern University Division of Rheumatology, Chicago, IL, 4Northwestern Feinberg School of Medicine, Chicago, IL, 5Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by vasculopathy and progressive fibrosis of the skin and internal organs. Individuals with SSc often…
  • Abstract Number: 2036 • ACR Convergence 2024

    CCN6 Gene Mutation Induces Mitochondrial Dysfunction: The Cause of Progressive Pseudo-rheumatoid Dysplasia

    Yanhong Li1, Xiufeng Bai2 and Yi Liu3, 1West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, 2West China Hospital, Sichuan University, Chengdu, Sichuan, China (People's Republic), 3West China Hospital of Sichuan University, Chengdu, Sichuan, China

    Background/Purpose: Progressive pseudo-rheumatoid dysplasia (PPRD) is a rare autosomal recessive disorder characterized by non-inflammatory joint issues that primarily affect the articular cartilage. This leads to…
  • Abstract Number: 0869 • ACR Convergence 2024

    Deciphering Pathogenic Phenotypes by Multi-modal Deep Single-cell Blood Immunophenotyping in Individuals At-risk for Rheumatoid Arthritis

    Jun Inamo1, Joshua Keegan2, Alec Griffith2, Tusharkanti Ghosh1, Alice Horisberger2, Kaitlyn Howard2, John Pulford2, Ekaterina Murzin2, Brandon Hancock2, Thomas Eisenhaure3, Salina Dominguez4, Miranda Gurra5, Siddarth Gurajala3, Anna Helena Jonsson1, Jennifer Seifert6, Marie Feser7, Jill Norris8, Ye Cao2, William Apruzzese9, S. Louis Bridges10, Vivian Bykerk11, Susan Goodman12, Laura Donlin11, Gary S. Firestein13, Joan Bathon14, Laura B. Hughes15, Darren Tabechian16, Andrew Filer17, Costantino Pitzalis18, Jennifer Anolik19, Larry Moreland20, Nir Hacohen21, Joel Guthridge22, Judith James22, Carla Cuda5, Harris Perlman5, Michael B. Brenner2, Soumya Raychaudhuri23, Jeffrey Sparks24, Michael Holers7, Kevin Deane25, James A. Lederer26, Deepak Rao26 and Fan Zhang27, and the Accelerating Medicines Partnership RA/SLE Network, 1University of Colorado School of Medicine, Aurora, CO, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Broad Institute of MIT and Harvard, Cambridge, 4Northwestern University, Chicago, 5Northwestern University, Chicago, IL, 6University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 7Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 8Colorado School of Public Health, Denver, CO, 9Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, 10Division of Rheumatology, Weill Cornell Medical College, New York, NY, 11Hospital For Special Surgery, New York, NY, 12Hospital for Special Surgery, New York 10025, NY, 13University of California, San Diego, La Jolla, 14Columbia University, New York, NY, 15University of Alabama at Birmingham Medicine, Birmingham, AL, 16University of Rochester Medical Center, Rochester, 17Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 18QMUL, Bromley Kent, United Kingdom, 19University of Rochester Medical Center, Rochester, NY, 20University of Colorado, Denver, CO, 21Broad Institute of MIT and Harvard, Boston, MA, 22Oklahoma Medical Research Foundation, Oklahoma City, OK, 23Brigham and Women's Hospital, Boston, MA, 24Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 25University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 26Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 27University of Colorado, Aurora, CO

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no effective prevention strategies. Single-cell technologies have been recently used to investigate established RA…
  • Abstract Number: 0962 • ACR Convergence 2024

    Characterizing the Contribution of Myeloid Cells to Limited and Diffuse Cutaneous Systemic Sclerosis

    Parker Jones1, Salina Dominguez2, Miranda Gurra3, Gaurav Gadhvi4, Tyler Therron2, Kathleen Aren5, Carla Cuda3, Monique Hinchcliff6, Harris Perlman3, Hadijat Makinde3 and Deborah Winter7, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern University, Chicago, IL, 4University of Michigan, Ann Arbor, MI, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Yale School of Medicine, Westport, CT, 7Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by multiorgan fibrosis. The two main subtypes are diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc…
  • Abstract Number: 2267 • ACR Convergence 2024

    A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis

    Maggie Louie1, Signe Fransen2, Katherine Dilger1, Kevin Lai1, Diana Abdueva3, David Chernoff4 and Jeffrey Curtis5, 1Aqtual Inc, Hayward, CA, 2Aqtual Inc., sf, CA, 3Aqtual Inc., Hayward, CA, 4SetPoint Medical, Sausalito, CA, 5University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Current rheumatoid arthritis (RA) treatments, including TNFa inhibitors (TNFi) and JAK inhibitors (JAKi), have transformed the management of RA by controlling symptoms and slowing…
  • Abstract Number: 0885 • ACR Convergence 2024

    Reproducible Single Cell Annotation of Programs Underlying T-cell Subsets, Activation States, and Functions

    Dylan Kotliar1, Michelle Curtis1, Ryan Agnew1, Kathryn Weinand1, Aparna Nathan2, Yuriy Baglaenko1, Yu Zhao1, Pardis Sabeti3, Deepak Rao4 and Soumya Raychaudhuri1, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Broad Institute, Boston, MA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: T-cells play a key role in the pathogenesis of autoimmune disease and in protection against cancer and infection. Consequently, there is widespread interest in…
  • Abstract Number: 0965 • ACR Convergence 2024

    Scleroderma Associated Interstitial Lung Disease Is Characterized by Aberrant Lung Epithelial Remodeling

    Monica Yang1, Fred Deiter2, Emily Flynn2, Seoyeon Lee3, Jessica Neely1, John Greenland2, Marina Sirota2 and Paul Wolters2, 1UCSF, San Francisco, CA, 2UCSF, SF, 3Yale, New Haven

    Background/Purpose: Interstitial lung disease (ILD) is present in a majority of systemic sclerosis (SSc) patients and the leading cause of SSc-related mortality. A subset of…
  • Abstract Number: 2516 • ACR Convergence 2024

    Exome-Wide Rare Variant Association Study of Takayasu’s Arteritis

    Yiming Luo1, Zuoming deng2, Kaitlin Quinn3, Keith Sikora4, Daniel Kastner5, Krzysztof Kiryluk1, Amr Sawalha6, Peter Merkel7 and Peter Grayson8, and the Vasculitis Clinical Research Consortium, 1Columbia University Irving Medical Center, New York, NY, 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4National Institutes of Health, Bethesda, MD, 5National Human Genome Research Institute, Bethesda, MD, Bethesda, MD, 6University of Pittsburgh, Pittsburgh, 7University of Pennsylvania, Philadelphia, PA, 8National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD

    Background/Purpose: Takayasu’s arteritis (TAK) is a rare inflammatory disease primarily involving the aorta and its major branches. Multiple genetic association studies on common variants in…
  • Abstract Number: 0887 • ACR Convergence 2024

    Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort

    Anastasia-Vasiliki Madenidou1, Gillian Rice2, Terence Garner3, Sarah Dyball4, Alice Chieng5, Ben Parker6, Tracy Briggs7, Adam Stevens3 and Ian Bruce8, 1Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 2Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, 3Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester and Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, 4Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom, 5Department of Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, Manchester, United Kingdom, 6Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 7Division of Evolution, Infection and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, 8Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Connective tissue diseases (CTDs) are a family of heterogeneous autoimmune diseases with overlapping clinical features. Not all patients with features suggestive of a mendelian…
  • Abstract Number: 1354 • ACR Convergence 2024

    The Association of Genetic Variation in PTPN22 and Rheumatoid Arthritis Disease Activity

    Thomas Riley1, Austin Wheeler2, Bryant England2, grant Cannon3, Sauer brian4, Gary Kunkel5, Katherine Wysham6, Beth Wallace7, Rachel Elam8, Paul Monach9, Andreas Reimold10, Gail Kerr11, Isaac Smith12, John Richards13, Iris Lee14, Rui Xiao15, Scott Damrauer15, Michael George15, Ted Mikuls2 and Joshua Baker15, 1Hopsital of the University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3University of Utah and Salt Lake City VA, Salt Lake City, UT, 4Salt Lake City VA/University of Utah, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 7Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 8Augusta University, Evans, GA, 9VA Boston Healthcare System, Boston, MA, 10Dallas VA Medical Center, Dallas, TX, 11Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 12Duke University Hospital, Durham, NC, 13Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 14Washington University in St Louis, Saint Louis, MO, 15University of Pennsylvania, Philadelphia, PA

    Background/Purpose: PTPN22 R620W is a common genetic variation that is a known risk factor for the development of autoimmune disease, including rheumatoid arthritis (RA). This…
  • Abstract Number: 2629 • ACR Convergence 2024

    Deciphering Salivary Gland Inflammation in Sjögren’s Syndrome Reveals Shared and Autoantibody-Specific Immune Cell Heterogeneity

    Jun Inamo1, Masaru Takeshita2, Katsuya Suzuki2, Kazuyuki Tsunoda2, Satoshi Usuda2, Junko Kuramoto2, Tsutomu Takeuchi3 and Yuko Kaneko4, 1University of Colorado School of Medicine, Aurora, CO, 2Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 3Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 4Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, JP, Shinjuku-ku, Tokyo, Japan

    Background/Purpose: Sjögren's syndrome (SS) is an autoimmune disease characterized by progressive immune cell-mediated destruction of the exocrine glands. SS patients have distinct clinical phenotypes based…
  • Abstract Number: 0018 • ACR Convergence 2023

    Alternative Splicing and Expected Protein Changes in Muscle Biopsies from Different Types of Idiopathic Inflammatory Myopathies

    Rayan Najjar1, Iago Pinal-Fernandez2, Andrew Mammen3 and Tomas Mustelin1, 1University of Washington, Seattle, WA, 2National Institutes of Health, Bethesda, MD, 3NIH, Bethesda, MD

    Background/Purpose: Alternative splicing of mRNA results in important biological impacts with increasing evidence implicating it in the pathology of autoimmune diseases. However, it is understudied…
  • Abstract Number: 0769 • ACR Convergence 2023

    Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort

    Austin Wheeler1, Joshua Baker2, Yangyuna Yang1, Punyasha Roul1, K Wysham3, Grant Cannon4, Gary Kunkel5, Gail Kerr6, Dana Ascherman7, Paul Monach8, Andreas Reimold9, Jill Poole1, Tony Merriman10, Ted R Mikuls11 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3VA Puget Sound/University of Washington, Seattle, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah, Salt Lake City, UT, 6Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 7University of Pittsburgh, Pittsburgh, PA, 8VA Boston Healthcare System, Boston, MA, 9University of Texas Southwestern Medical Center, Dallas, TX, 10University of Alabama at Birmingham, Birmingham, AL, 11Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Although some clinical and genetic risk…
  • Abstract Number: 2105 • ACR Convergence 2023

    Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases

    Hiroaki Tanaka1, Yukinori Okada2, Shingo Nakayamada1, Yusuke Miyazaki3, Kyuto Sonehara4, Shinichi Namba5, Suguru Honda6, Yuya Shirai7, Kenichi Yamamoto5, Katsunori Ikari8, Masayoshi Harigai9, KOSHIRO SONOMOTO10 and Yoshiya Tanaka1, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, 3The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, 4University of Tokyo, Tokyo, Japan, 5Osaka University, Osaka, Japan, 6Tokyo Women's Medical University, Tokyo, Japan, 7Osaka University, Suita, Japan, 8Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 9Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 10University of Occupational and Environmental Health, Beppu, Japan

    Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology